Generic Name


Therapeutic Category


Tizanidine Hydrochloride

Tizanidine Hydrochloride 2mg Tablets

Muscle Relaxant



    Each uncoated tablet contains:

    Tizanidine Hydrochloride equivalent to Tizanidine       2 mg

    ZANID is a white coloured, round, flat, uncoated tablet with breakline on one side


    Pharmacotherapeutic Group:  Muscle relaxants, alpha2 adrenergic agonist

    Pharmacodynamic properties: Tizanidine a α2 adrenergic agonist is a centrally acting muscle relaxant structurally related to clonidine. It reduces spasticity by increasing presynaptic inhibition of motor neurons and has no direct effect on skeletal muscle, the neuromuscular junction or on monosynaptic spinal reflexes.

    Pharmacokinetic properties:

    Absorption: Absorbed from the GI tract (oral); Peak plasma concentrations: 1-2 hour, Bioavailability: 40%

    Distribution: Protein binding: 30% .Elimination half-life: 2-4 hr

    Metabolism: Extensive hepatic first pass metabolism mainly via the CYP 450 isoenzyme CYP1A2.

    Elimination: Via urine (mainly as inactive metabolites)


    Migraine, back pain, spasm, multiple sclerosis, cramps, injury, spasticity


    Adult: >18 years: Initially, 2 mg once daily increased according to response by 2 mg increments at intervals of at least 3-4 days up to 24 mg daily in 3-4 divided doses. Max: 36 mg/day 

    Painful muscle spasm associated with musculoskeletal conditions.

    Adult: >18 year: 2-4 mg tid



    • May be taken with or without food.

    Food Interaction: 

    • Caffeine may increase the blood levels and effects of tizanidine. Alcohol may increase the side effects.

    Pregnancy:   Category C

    Storage:  Store tablet between 15-30 °C.

    Missed dose: 

    • Take the missed dose as soon as you remember
    • Skip the missed dose if it is almost time for your next scheduled dose
    • Do not take extra medicine to make up the missed dose.

    Hypersensitivity, concomitant ciprofloxacin or fluvoxamine or other potent CYP1A2 inhibitors.


    Hepatic or renal insufficiency. Children, elderly, pregnancy and lactation. Monitor LFT regularly. Stop treatment if liver enzymes are raised persistently >3 times upper limit of normal range. Avoid abrupt withdrawal of therapy.


    Severe AEs: Hepatitis

    Common AEs: Drowsiness, fatigue, dizziness, insomnia, headache, anxiety, nausea, dryness of mouth, GI disturbances, hypotension, bradycardia, muscle pain and weakness, transient increase in serum transaminases, hallucinations.


    Potentiates hypotensive effect of antihypertensives. Increased CNS effects with alcohol and CNS depressants. Increased bradycardia with β-blockers and digoxin. Increased serum concentration of tizanidine with CYP1A2 inhibitors.


    Each box is supplied with 10 strips of 10 tabs packed in blisters.